Alona Zer
- Oncology top 1%
- Pulmonary and Respiratory Medicine top 1%
- Molecular Biology
- Immunology top 10%
- Cancer Research top 5%
- Co-authors
- Elizabeth DudnikFederico CappuzzoAlessandro MorabitoHans‐Georg KoppTarek MekhailHoward WestNiels ReinmuthVenice Archer
- Topics
- Lung Cancer Treatments and Mutations (59 papers)Cancer Immunotherapy and Biomarkers (32 papers)Lung Cancer Research Studies (31 papers)
- Partner nations
- IsraelUnited StatesCanada
In The Last Decade
Alona Zer
118 papers receiving 3.2k citations
Hit Papers
Peers
Comparison fields: 5 of 97
- Oncology 2.4k
- Pulmonary and Respiratory Medicine 1.8k
- Molecular Biology 380
- Immunology 342
- Cancer Research 332
Countries citing papers authored by Alona Zer
This map shows the geographic impact of Alona Zer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alona Zer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alona Zer more than expected).
Fields of papers citing papers by Alona Zer
This network shows the impact of papers produced by Alona Zer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alona Zer. The network helps show where Alona Zer may publish in the future.
Co-authorship network of co-authors of Alona Zer
This figure shows the co-authorship network connecting the top 25 collaborators of Alona Zer. A scholar is included among the top collaborators of Alona Zer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alona Zer. Alona Zer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 4 | |
| 3 | 1 | |
| 4 | 4 | |
| 5 | 3 | |
| 6 | 5 | |
| 7 | 54 | |
| 8 | 4 | |
| 9 | 4 | |
| 10 | 8 | |
| 11 | 1 | |
| 12 | 37 | |
| 13 | 11 | |
| 14 | Circulating Tumor DNA T790M Testing as a Predictor of Osimertinib Efficacy in Epidermal Growth Factor Receptor Mutant Non-small Cell Lung Cancer: A Single Center Experience. | 1 |
| 15 | 1 | |
| 16 | 6 | |
| 17 | Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trialbreakdown → | 1137 |
| 18 | 17 | |
| 19 | 1 | |
| 20 | 1 |
About Alona Zer
Alona Zer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 127 papers that have together received 3.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (59 papers), Cancer Immunotherapy and Biomarkers (32 papers) and Lung Cancer Research Studies (31 papers). The work is most often cited by research in Oncology (2.4k citations), Pulmonary and Respiratory Medicine (1.8k citations) and Internal Medicine (103 citations). Alona Zer has collaborated with scholars based in Israel, United States and Canada. Frequent co-authors include Elizabeth Dudnik, Federico Cappuzzo, Alessandro Morabito, Hans‐Georg Kopp, Tarek Mekhail, Howard West, Niels Reinmuth, Venice Archer, Marcin Kowanetz and Michael McCleod. Their work appears in journals such as Journal of Clinical Oncology, Blood and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.